1. Home
  2. OTIS vs BIIB Comparison

OTIS vs BIIB Comparison

Compare OTIS & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Otis Worldwide Corporation

OTIS

Otis Worldwide Corporation

HOLD

Current Price

$77.98

Market Cap

31.5B

Sector

Technology

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$183.22

Market Cap

27.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OTIS
BIIB
Founded
1853
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.5B
27.3B
IPO Year
2019
1996

Fundamental Metrics

Financial Performance
Metric
OTIS
BIIB
Price
$77.98
$183.22
Analyst Decision
Hold
Buy
Analyst Count
9
26
Target Price
$99.63
$203.16
AVG Volume (30 Days)
3.0M
1.2M
Earning Date
04-22-2026
04-29-2026
Dividend Yield
2.27%
N/A
EPS Growth
N/A
N/A
EPS
0.87
8.79
Revenue
N/A
$9,890,600,000.00
Revenue This Year
$6.94
N/A
Revenue Next Year
$4.83
N/A
P/E Ratio
$89.07
$20.57
Revenue Growth
N/A
2.22
52 Week Low
$75.27
$115.28
52 Week High
$101.42
$202.41

Technical Indicators

Market Signals
Indicator
OTIS
BIIB
Relative Strength Index (RSI) 41.68 50.87
Support Level $75.27 $181.24
Resistance Level $92.98 $184.16
Average True Range (ATR) 1.90 4.55
MACD 0.01 0.70
Stochastic Oscillator 27.07 55.86

Price Performance

Historical Comparison
OTIS
BIIB

About OTIS Otis Worldwide Corporation

Otis is the largest global elevator and escalator supplier by revenue with around 18% global market share. In 1854 Otis' founder and namesake Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed. The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15- to 20-year useful life of an elevator. As the largest global OEM, Otis has amassed an installed base under service that exceeds 2 million elevators. Its business model is similar to that of its closest competitors Kone, Schindler, and TK Elevator.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: